Azitra gets NYSE American approval for compliance plan Dec 17, 2025 04:10PM
Azitra denies report of $44 million securities offering Nov 7, 2025 06:00AM
Azitra reports preclinical data for ichthyosis vulgaris treatment Oct 20, 2025 08:02AM
AZTR receives NYSE delisting warning over equity requirement Oct 3, 2025 04:45PM
Azitra, Inc (AZTR) Files for 2.25M Share Offering by Selling Stockholders Jul 18, 2025 04:15PM


Jun 17, 2025 08:02AM Azitra, Inc (AZTR) Reports Safety Data from Phase 1b Trial in Netherton Syndrome
May 14, 2025 05:25PM Azitra, Inc. (AZTR) Reports Q1 Loss of $0.23
Apr 24, 2025 04:06PM Azitra, Inc (AZTR) Announces $20M Share Purchase Agreement with Alumni Capital to Fund Clinical Pipeline
Feb 26, 2025 11:47AM Azitra, Inc. (AZTR) PT Lowered to $2 at Maxim Group
Feb 4, 2025 02:20PM Azitra, Inc (AZTR) Prices 3.34M Share Offering at $0.2785/sh
Jan 15, 2025 08:30AM Azitra, Inc (AZTR) Prices 4.86M Share Offering at $0.30/sh
Jan 14, 2025 04:06PM Azitra, Inc (AZTR) Announces Proposed Share Offering
Nov 13, 2024 05:01PM Azitra, Inc. (AZTR) Reports Q3 Loss of $0.17
Sep 24, 2024 08:04AM Azitra (AZTR) Announces Late-Breaking Presentation at the European Academy of Dermatology and Venereology Congress
Sep 18, 2024 09:00AM Azitra, Inc (AZTR) Receives Fast Track Designation for ATR-04 for Skin Rash from EGFR Inhibitors
Aug 28, 2024 08:31AM Azitra, Inc (AZTR) Announces First Patient Dosed in Phase 1b Trial of ATR-12 for Netherton Syndrome
Aug 22, 2024 09:02AM Azitra, (AZTR) Receives Study May Proceed letter from the FDA for IND to Treat Skin Rash from EGFR Inhibitors
Aug 13, 2024 10:13AM Azitra, Inc. (AZTR) Reports Q2 Loss of $2.74
Jul 24, 2024 05:54AM Azitra, Inc (AZTR) Prices 6.66M Share Offering at $1.50/sh
Jul 23, 2024 08:01AM Azitra, Inc (AZTR) Strengthens Global Intellectual Property Portfolio with Newly Granted and Allowed Patents
Jun 27, 2024 04:05PM Azitra, Inc (AZTR) Announces 1:30 Reverse Share Split